|
Non-Hodgkin’s Lymphoma, Follicular:
-
SWOG 0016: A Phase III Trial of CHOP vs. CHOP +
Rituximab vs. CHOP + Iodine-131-Labeled Monoclonal Anti-B1
Antibody (Tositumomab) For Treatment of Newly Diagnosed
Follicular Non-Hodgkin's Lymphomas (THE CHOP ONLY ARM OF
THIS STUDY WAS PERMANENTLY CLOSED, EFFECTIVE 12/15/02)
-
PSOC 2002: A Phase II Study
Evaluating the Efficacy of Rituximab and Dexamethasone in
CD20 Positive Low Grade and Follicular Non-Hodgkin's
Lymphoma
Non-Hodgkin’s Lymphoma, Large B-Cell:
-
SWOG 0313: Evaluation of CHOP Plus Involved Field
Radiotherapy followed by Yttrium-90 Ibritumomab Tiuxetan for
Stages I, IE and non-bulky Stages II and IIE, CD20 Positive,
High-risk Localized, Aggressive Histologies of Non-Hodgkin's
Lymphoma, Phase II
-
SWOG 0515: Phase II Trial of Standard Dose
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
(CHOP) and Rituximab Plus Bevacizumab for Advanced Stage
Diffuse Large B-Cell NHL
-
SWOG 0520: Phase II Study of PXD101 (NSC-726630) in
Relapsed and Refractory Agressive B-Cell
-
SWOG 0433: A Phase II Study of Iodine-131-Labeled
Monoclonal Anti-B1 Antibody (I-131 Tositumomab) in
Combination With Cyclophosphamide, Doxorubicin, Vincristine,
Prednisone and Rituximab Therapy for Patients >= Age 60 With
Advanced Stage Diffuse Large B-Cell NHL
-
CTSU C50303: A Phase III Randomized Study of R-CHOP v.
Dose-adjusted EPOCH-R with Molecular Profiling in Untreated
De Novo Diffuse Large B-Cell Lymphomas
-
PSOC 2301: A Phase II Study of Bexxar Consolidation
in Patients with B-Cell Chronic Lymphocytic Leukemia
Following Fludarabine and Rituximab Chemotherapy (includes
patients with small lymphocytic lymphoma)
Non-Hodgkin’s Lymphoma, Mantle Cell:
Non-Hodgkin’s Lymphoma,T-Cell:
Hodgkin’s Lymphoma, Recurrent or Primary
Refractory:
For more information on the above clinical
trials:
Cheryl Patz, RN, OCN, CCRC, 360.715.4133
Return to previous page
|